Rare diseases

Progeria (pronunciation pro-jeer-e-uh), otherwise called Hutchinson-Gilford condition, is an exceptionally uncommon, reformist hereditary problem that makes youngsters age quickly, beginning in their initial two years of life.

Youngsters with progeria for the most part seem typical upon entering the world. During the primary year, signs and side effects, for example, moderate development and balding, start to show up.

Heart issues or strokes are the inevitable reason for death in most youngsters with progeria. The normal future for a youngster with progeria is around 13 years. Some with the illness may kick the bucket more youthful and others may live more, even as long as 20 years.

There’s no solution for progeria, however continuous examination shows some guarantee for treatment

Bollywood Film Paa (2009) depicts story of such a child who suffers from Progeria.

Side Effects

Typically inside the primary year of life, development of a kid with progeria eases back extraordinarily, yet engine advancement and knowledge stay ordinary.


Signs and side effects of this reformist problem incorporate an unmistakable appearance:

• Eased back development, with sub optimal tallness and weight
• Limited face, little lower jaw, slender lips and bent nose
• Head excessively enormous for the face
• Conspicuous eyes and deficient conclusion of the eyelids
• Balding, including eyelashes and eyebrows
• Diminishing, patchy, wrinkled skin
• Obvious veins
• Sharp voice

Additional Syptoms for Progeria

Signs and side effects additionally incorporate medical problems:

• Extreme reformist heart and vein (cardiovascular) infection.
• Solidifying and fixing of skin on the storage compartment and limits (like scleroderma)
• Postponed and unusual tooth development
• Some meeting misfortune
• Loss of fat under the skin and loss of bulk
• Skeletal irregularities and delicate bones
• Solid joints
• Hip separation
• Insulin obstruction
• When to see a specialist

Progeria is generally identified in outset or youth, frequently at normal tests, when an infant first gives the trademark indications of untimely maturing.

In the event that you notice changes in your kid that could be signs and side effects of progeria, or you have any worries about your youngster’s development or advancement, make a meeting with your kid’s PCP.


A solitary quality change is answerable for progeria. The quality, known as lamin A (LMNA), makes a protein vital for holding the middle (core) of a cell together. At the point when this quality has an imperfection (change), a strange type of the Lamin “A”P rotein called progerin is delivered and makes cells insecure. This seems to prompt progeria’s maturing cycle.

In contrast to numerous hereditary transformations, progeria is once in a while passed down in families. The quality transformation is an uncommon, chance event in most of cases.

Lamin A is a major component of a protein scaffold on the inner edge of the nucleus called the nuclear lamina that helps organize nuclear processes such as RNA and DNA synthesis.

Prelamin A contains a CAAX box at the C-terminus of the protein (where C is a cysteine and A is any aliphatic amino acids). This ensures that the cysteine is farnesylated and allows prelamin A to bind membranes, specifically the nuclear membrane. After prelamin A has been localized to the cell nuclear membrane, the C-terminal amino acids, including the farnesylated cysteine, are cleaved off by a specific protease. The resulting protein, now lamin A, is no longer membrane-bound and carries out functions inside the nucleus.

In HGPS, the recognition site that the enzyme requires for cleavage of prelamin A to lamin A is mutated. Lamin A cannot be produced, and prelamin A builds up on the nuclear membrane, causing a characteristic nuclear blebbing. This results in the symptoms of progeria, although the relationship between the misshapen nucleus and the symptoms is not known.

A study that compared HGPS patient cells with the skin cells from young and elderly normal human subjects found similar defects in the HGPS and elderly cells, including down-regulation of certain nuclear proteins, increased DNA damage, and demethylation of histone, leading to reduced heterochromatin. Nematodes over their lifespan show progressive lamin changes comparable to HGPS in all cells but neurons and gametes. These studies suggest that lamin A defects are associated with normal aging

Other comparable disorder

There are other progeroid conditions that do run in families. These acquired conditions cause quick maturing and an abbreviated life expectancy:

Wiedemann-Rautenstrauch disorder, otherwise called neonatal progeroid condition, begins in the belly, with signs and side effects of maturing evident upon entering the world.

Werner disorder, otherwise called grown-up progeria, starts in the high schooler years or early adulthood, causing untimely maturing and conditions run of the mill of mature age, for example, waterfalls and diabetes.

Danger factors

There are no referred to factors, for example, way of life or natural issues, which increment the danger of having progeria or of bringing forth a kid with progeria. Progeria is amazingly uncommon. For guardians who have had one youngster with progeria, the odds of having a second kid with progeria are around 2 to 3 percent.


Kids with progeria typically create serious solidifying of the supply routes (atherosclerosis). This is a condition wherein the dividers of the conduits — veins that convey supplements and oxygen from the heart to the remainder of the body — harden and thicken, frequently limiting blood stream.

Most youngsters with progeria kick the bucket of complexities identified with atherosclerosis, including:

Issues with veins that supply the heart (cardiovascular issues), bringing about coronary episode and congestive cardiovascular breakdown
Issues with veins that supply the mind (cerebrovascular issues), bringing about stroke.

Other medical issues often connected with maturing —, for example, joint inflammation, waterfalls and expanded malignant growth hazard — normally don’t create as a component of the course of progeria.


In November 2020, the U.S. Food and Drug Administration approved lonafarnib, which helps prevent buildup of defective progerin and similar proteins. A clinical trial in 2018 points to significantly lower mortality rates ~ treatment with lonafarnib alone compared with no treatment (3.7% vs. 33.3%) ~ at a median post-trial follow-up time span of 2.2 years.

Other treatment options have focused on reducing complications (such as cardiovascular disease) with coronary artery bypass surgery and low-dose aspirin.

Growth hormone treatment has been attempted. The use of Morpholinos has also been attempted in mice and cell cultures in order to reduce progerin production. Antisense Morpholino oligonucleotides specifically directed against the mutated exon 11–exon 12 junction in the mutated pre-mRNAs were used.

A type of anticancer drug, the farnesyltransferase inhibitors (FTIs), has been proposed, but their use has been mostly limited to animal models. A Phase II clinical trial using the FTI lonafarnib began in May 2007. In studies on the cells another anti-cancer drug, rapamycin, caused removal of progerin from the nuclear membrane through autophagy. It has been proved that pravastatin and zoledronate are effective drugs when it comes to the blocking of farnesyl group production.

Farnesyl Transferase Inhibitors (FTIs) are drugs that inhibit the activity of an enzyme needed to make a link between progerin proteins and farnesyl groups. This link generates the permanent attachment of the progerin to the nuclear rim. In progeria, cellular damage can occur because that attachment occurs, and the nucleus is not in a normal state. Lonafarnib is an FTI, which means it can avoid this link, so progerin cannot remain attached to the nucleus rim, and it now has a more normal state.

Studies of sirolimus, an mTOR Inhibitor, demonstrate that it can minimize the phenotypic effects of progeria fibroblasts. Other observed consequences of its use are abolishing nuclear blebbing, degradation of progerin in affected cells, and reducing insoluble progerin aggregates formation. These results have been observed only in vitro and are not the results of any clinical trial, although it is believed that the treatment might benefit HGPS patients.


This article is merely a compilation of information availble on web in a systematic way. The writer of this article, for Pedia Hut, does not belong from medical field. Thus, in case of any doubt please consut a doctor. This article merely aims to spread relevant information at one place.

Spread the love